LY3561774 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dyslipidemias

Conditions

Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia

Trial Timeline

Jul 20, 2022 → May 23, 2024

NCT ID

NCT05256654

About LY3561774 + Placebo

LY3561774 + Placebo is a phase 2 stage product being developed by Eli Lilly for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT05256654. Target conditions include Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases.

What happened to similar drugs?

6 of 6 similar drugs in Dyslipidemias were approved

Approved (6) Terminated (0) Active (0)

✅Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved

✅Atorvastatin + AtorvastatinPfizerApproved

✅AtorvastatinPfizerApproved

✅Atorvastatin + Atorvastatin + AtorvastatinPfizerApproved

✅AtorvastatinPfizerApproved

✅Atorvastatin + Atorvastatin + AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05256654	Phase 2	Completed	Jul 20, 2022	May 23, 2024	Dyslipidemias
NCT04644809	Phase 1	Completed	Nov 30, 2020	May 17, 2022	Dyslipidemias

Competing Products

15 competing products in Dyslipidemias

See all competitors

Product	Company	Stage	Hype Score
LY3202328 + Placebo + Atorvastatin + Simvastatin	Eli Lilly	Phase 1	29
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg	Yuhan	Approved	43
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC	Eli Lilly	Phase 1	29
LY3885125 + Placebo	Eli Lilly	Phase 1	21
LY3561774 + Placebo	Eli Lilly	Phase 1	29
LY2484595 + Placebo + Atorvastatin	Eli Lilly	Phase 2	35
Atorvastatin + Atorvastatin	Pfizer	Approved	43
Atorvastatin	Pfizer	Approved	43
Atorvastatin + Atorvastatin + Atorvastatin	Pfizer	Approved	43
Vupanorsen + Placebo	Pfizer	Phase 2	35
Atorvastatin	Pfizer	Approved	43
Atorvastatin + Atorvastatin + Atorvastatin	Pfizer	Approved	43
GWP42003 + GWP42003 + GWP42004 + Placebo	Jazz Pharmaceuticals	Phase 2	32
ARO-APOC3	Arrowhead Pharmaceuticals	Phase 2	32
ARO-ANG3 + sterile normal saline (0.9% NaCl)	Arrowhead Pharmaceuticals	Phase 1	26